AI assistant
Sending…
Niagen Bioscience, Inc. — Director's Dealing 2010
Apr 6, 2010
32418_dirs_2010-04-06_6af2226e-1c81-463c-b394-1acbcd07f609.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2009-05-13
Reporting Person: Varvaro Thomas C (Director, Chief Finanical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2009-05-13 | Stock Option (Right to buy) | $0.50 | A | 75000 | Acquired | 2019-05-13 | Common Stock (75000) | Direct |
Footnotes
F1: 18,750 options become exercisable May 13, 2010 and 1,562 become exercisable each odd month and 1,563 become exercisable each even month for 36 months thereafter.
More from Niagen Bioscience, Inc.
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Major Shareholding Notification
2026
Jan 30
Regulatory Filings
2025
Dec 22
Director's Dealing
2025
Nov 17
Regulatory Filings
2025
Nov 6